Moderna stock plunges as guidance cut on low EU sales, U.S. vaccine competition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 1, 2024 6:33 AM EDTReports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)
Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion
Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June
Announced positive Phase 3 data for combination vaccine against influenza and COVID-19
Announced positive Phase 3 data for next-generation COVID-19 vaccine
CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:... More
